NOTCH1 and B-cell chronic lymphocytic leukemia: These data also require further investigation, but it seems conceivable that the use of monoclonal antibodies appears to be a possible therapeutic strategy in CLL patients with mutated Notch 1 and aggressive disease [84] (Figure 1).